| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.23 | 3e-09 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.29 | 2e-08 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-07 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.24 | 4e-06 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.17 | 4e-05 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |